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We retrospectively examined the relationship between blood biomarkers, in particular
the historical mean phenylalanine to tyrosine (Phe:Tyr) ratio, and cerebral glucose
metabolism. We hypothesized that the historical mean Phe:Tyr ratio would be
more predictive of cerebral glucose metabolism than the phenylalanine (Phe)
level alone. We performed a retrospective case series analysis involving 11 adult
classical phenylketonuria/hyperphenylalaninemia patients under the care of an Inherited
Metabolic & Neuropsychiatry Clinic who had complained of memory problems, collating
casenote data from blood biochemistry, and clinical [18F]fluorodeoxyglucose positron
emission tomography ([18F]FDG PET). The Phe:Tyr ratio was calculated for individual
blood samples and summarized as historical mean Phe:Tyr ratio (Phe:Tyr) and historical
standard deviation in Phe:Tyr ratio (SD-Phe:Tyr), for each patient. Visual analyses
of [18F]FDG PET revealed heterogeneous patterns of glucose hypometabolism for
eight patients. [18F]FDG PET standardized uptake was negatively correlated with Phe
in a large cluster with peak localized to right superior parietal gyrus. Even larger
clusters of negative correlation that encompassed most of the brain, with frontal
peaks, were observed with Phe:Tyr, and SD-Phe:Tyr. Our case series analysis provides
further evidence for the association between blood biomarkers, and cerebral glucose
hypometabolism. Mean historical blood Phe:Tyr ratio, and its standard deviation over
time, appear to be more indicative of global cerebral glucose metabolism in patients
with memory problems than Phe.
Keywords: phenylketonuria, hyperphenylalaninemia, [18F]fluorodeoxyglucose PET, phenylalanine:tyrosine ratio,
intellectual function
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INTRODUCTION
Phenylketonuria (PKU) is an inherited metabolic disease, with
prevalence rates of around 1:10,000 births in Northern Europe
(Loeber, 2007). It occurs due to a deficiency in the phenylalanine
hydroxylase (PAH) enzyme, which metabolizes the amino acid
phenylalanine (Phe) into tyrosine (Tyr). Tyr then undergoes
further metabolism into melanin, and thyroxine, and also
is a precursor to neurotransmitters including dopamine and
adrenaline (Schuck et al., 2015).
Phenylalanine hydroxylase deficiency can occur to varying
degrees, resulting in differences in the severity of phenotypes.
“Classical” PKU is the most severe of the phenotypes, with a
near complete deficiency of PAH activity. Pre-treatment Phe
levels over 1200 µmol/L are considered diagnostic for “classical”
PKU, whereas levels between 600 and 1200 µmol/L are referred
to as “atypical/mild” PKU, and 120–600 µmol/L as (mild)
hyperphenylalaninemia (HPA) (Blau et al., 2010). However, in
the adult clinical setting, the distinction between HPA and mild
PKU phenotypes is often arbitrary due to the lack of historical
data, and mostly based on patients’ self-reported natural protein
intake/tolerance and their periodic blood Phe.
Following the implementation of national birth screening
and dietary control measures, there has been a decrease
in the rates of complications resulting from the severe
phenotype, which include microcephaly, seizures, behavioral
difficulties, reduced intelligence, severe learning disability and
tremor (Trefz et al., 2000; Williams et al., 2008). However,
the identification of other neurocognitive symptoms has
increased. For example, a meta-analysis found a negative
correlation between IQ and Phe concentration (Fonnesbeck
et al., 2013). Frontal executive dysfunction has also been
identified in patients with PKU. Nardecchia et al. (2015)
conducted a long term follow up study in which they
identified relative impairment of function in executive
abilities, visuospatial and attentional skills, compared to
controls. The phenylalanine-to-tyrosine (Phe:Tyr) ratio has
been correlated with executive function measures, to a greater
extent that Phe alone.
Whilst neuroimaging is not routinely performed in
phenylketonuria, cerebral glucose utilization has been studied
sparingly. In the largest study to date, Wasserstein et al.
reported that plasma phenylalanine was negatively correlated
with relative cerebral glucose metabolic rates, as measured
via [18F]fluorodeoxyglucose positron emission tomography
(PET), in ten patients with classical PKU who performed a
verbal learning task during the tracer uptake period. The PKU
group also had lower cortical relative glucose metabolic rate
than the control group, a finding that was consistent with
smaller clinical (Yanai et al., 1987; Hasselbalch et al., 1996;
Ficicioglu et al., 2013) and animal studies (Qin and Smith, 2007;
Dienel and Cruz, 2016).
It is not yet known whether cerebral glucose metabolism
is also reduced in patients with classical PKU or HPA
and memory problems. Our case series analysis aimed to
investigate the relationships between blood biomarkers, in
particular the historical mean Phe:Tyr ratio, and cerebral glucose
metabolism. Based on the studies of executive function in
phenylketonuria, we hypothesized that the Phe:Tyr ratio would
be more predictive of cerebral glucose metabolism than the
Phe level alone.
MATERIALS AND METHODS
A retrospective case series analysis was performed in 11
adult patients under the care of the Inherited Metabolic &
Neuropsychiatry Clinic at St Thomas’ Hospital, London who
complained of memory problems. We collated casenote data
from neuropsychiatric assessments, blood biochemistry tests, and
clinical [18F]fluorodeoxyglucose positron emission tomography
([18F]FDG PET). Genetic data were unavailable as gene analysis
was not routinely performed.
Ethics Approval and Patient Consent
Statement
Ethical approval was not required for this retrospective case
series analysis of data that had already been acquired as part
of routine clinical care. All patients provided verbal informed
consent for the data acquisition as part of routine clinical care.
Patients were informed that their anonymized data could be used
for research and teaching.
Blood Biochemistry
Blood biochemistry test results included repeated Phe and Tyr
measurements. The Phe:Tyr ratio was calculated for individual
blood samples at each time point and subsequently averaged
to give a historical mean Phe:Tyr ratio for each patient. We
also computed the standard deviation in historical Phe:Tyr
ratio for each patient. All blood samples were processed in the
same laboratory.
[18F]FDG PET
[18F]FDG PET scans were acquired using several different
models of the Discovery PET/CT scanner series (ST/STE/710)
from GE Healthcare (Little Chalfont, United Kingdom).
The images, reconstructed iteratively using ordered subsets
expectation maximization (OSEM), were reported clinically by
two Consultants in Nuclear Medicine using visual interpretation
and re-reviewed at a later stage for the purposes of this case
series analysis by SFB to confirm consistency of reporting. In
order to allow quantitative analyses, the images initially displayed
in absolute counts scaled to the maximum value were displayed
as standardized uptake values (SUVs), calculated according to









The SUV images were subsequently aligned to the [18F]FDG
PET template image in MNI space provided with SPM12,
via non-linear registration. The SUV images were smoothed
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with an isotropic Gaussian filter of eight millimeters full-
width at half-maximum to account for modest differences
between scanners.
Voxel-By-Voxel Analyses
The relationships between SUV and Phe, SUV and the standard
deviation in Phe (SD-Phe), SUV and Phe:Tyr, and SUV
and the standard deviation in Phe:Tyr (SD-Phe:Tyr), were
interrogated separately on a voxel-by-voxel basis via multisubject
simple regression using threshold-free cluster enhancement as
implemented in FSL version 5.0.91 with the “randomize” tool,
version 2.9. We used 10,000 permutations, an explicit whole brain
mask, and a stringent threshold of p< 0.05 after family-wise error
correction.
The patients were also compared on a voxel-by-voxel
basis with 25 healthy controls (median ± interquartile
range 35.0 ± 12 years, minimum 29 years, maximum
40 years; 13 females) that had been scanned at a different
Centre using a GE Discovery ST PET/CT scanner. A two-
sample t-test was performed using threshold-free cluster
enhancement as implemented in FSL-randomize, with an
additional age covariate and proportional scaling. The number
of permutations, masking and thresholds were described
above.
RESULTS
Six females and five males were included in the case series
analysis. Age and blood biochemistry data are summarized in
Table 1. Eight patients had a diagnosis of classical PKU and three
had a diagnosis of HPA.
Three patients, one with classical PKU and two with HPA,
had stopped adhering to a low Phe diet before reaching 10 years
of age; six patients with classical PKU stopped adhering to it
between 11 and 20 years of age; and the remaining two patients,
one with classical PKU and one with HPA, had adhered to it
throughout their life.
Longitudinal historical Phe levels were available for 10 patients
(median ± interquartile range 12.5 ± 15 samples, minimum 8,
maximum 29) and repeated historical Tyr levels were available for
nine (12± 15 samples, minimum 6, maximum 25). Therefore, the
mean historical Phe:Tyr ratios and standard deviation in Phe:Tyr
ratios were calculated for nine patients. Phe levels at the time of
scan were available for all 11 patients.
Neuroimaging Findings
Visual Interpretation
[18F]FDG PET revealed heterogeneous patterns of glucose
metabolism for eight of the 11 patients (Figure 1).
Hypometabolic distributions was summarized as: frontal
(2), temporal (1), frontotemporal (1), frontotemporoparietal
(3), and temporoparietal (1) patterns. Hypermetabolism
was not identified.
1https://fsl.fmrib.ox.ac.uk/fsl/fslwiki




Age at scan 31 13 18 40




103 13 73 121
Perceptual
Reasoning Index
94 15 71 134
Working Memory
Index
89 12 74 103
Processing Speed
Index
95 16 75 108
Full-scale IQ 92 19 71 107
Phenylalanine at
scan
(µmol/ml; n = 11)
742 434 237 1304
Mean historical
phenylalanine
(µmol/ml; n = 10)




(µmol/ml; n = 10)
193 95 50 358
Mean historical
Phe:Tyr ratio (n = 9)
16 11 3 37
Standard deviation
in historical Phe:Tyr
ratio (n = 9)
11 6 1 20
Voxel-By-Voxel Analyses – Correlations
The SUV was not positively correlated with any of the
examined variables.
A significant negative correlation was observed between SUV
and Phe, in an extremely large cluster (577,784 mm3), with
peak localized to the right superior parietal gyrus (Table 2 and
Supplementary Material, Figures 1, 2). The cluster encompassed
approximately 31% of the brain mask by volume. A second cluster
of 1,991 mm3 was observed with peak localized to the right
caudate nucleus.
There was no significant correlation between SUV and SD-
Phe.
A significant negative correlation was observed between SUV
and Phe:Tyr, in an extremely large cluster (1,603,968 mm3)
with peak localized to the right middle frontal gyrus (Table 2
and Supplementary Figures 3, 4). The cluster encompassed
approximately 86% of the brain mask.
A significant negative correlation was also observed
between SUV and SD-Phe:Tyr, in an extremely large cluster
(1,641,632 mm3) with peak localized to the right middle frontal
gyrus (Table 2 and Supplementary Figures 5, 6). The cluster
encompassed approximately 88% of the brain mask.
Voxel-By-Voxel Analyses – Comparison With Controls
The patients had significantly lower uptake than controls in five
clusters, the largest of which (45,464 mm3) had peak in the right
inferior and middle temporal gyri (Table 3 and Supplementary
Figure 7). The patients had significantly greater uptake than
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FIGURE 1 | Examples of patterns of glucose metabolism revealed by [18F]FDG PET. The panel on the left depicts the mean of two patients who had scans that were
reported as normal. The panel on the right depicts marked, widespread frontotemporoparietal hypometabolism sparing the occipital cortex, seen in patient 6, a
40-year-old male with full-scale IQ of 90 who ceased adherence to the low phenylalanine diet before he reached 10 years of age. His most recent blood spot
phenylalanine measurement prior to the scan was 1200 µmol/ml. Based on 25 phenylalanine and 22 tyrosine measurements, his mean ± standard deviation
historical phenylalanine was 877.2 ± 183.6 µmol/ml, and his Phe:Tyr ratio was 89.2 ± 52.6.
TABLE 2 | Clusters of negative correlation between SUV and Phe, between SUV and Phe:Tyr, and between SUV and SD-Phe:Tyr.
SUV-Phe
Peak Centre-of-Gravity
Volume (mm3) x, y, z(mm) Region Name x, y, z(mm) Region Name
Negative 577,784 42, −38, 42 Right superior parietal gyrus 08, −19, 22 Corpus callosum
1,992 14, 16, 02 Right caudate nucleus 14, 13, 06 Right caudate nucleus
Positive – – – – –
SUV-Phe:Tyr
Peak Centre-of-Gravity
Volume (mm3) x, y, z(mm) Region Name x, y, z(mm) Region Name
Negative 1,603,968 44, 46, −02 Right middle frontal gyrus 03, −23, 10 Third ventricle
Positive – – – – –
SUV-SD-Phe:Tyr
Peak Centre-of-Gravity
Volume (mm3) x, y, z(mm) Region Name x, y, z(mm) Region Name
Negative 1,641,632 42, 44, 00 Right middle frontal gyrus 03, −23, 10 Third ventricle
Positive – – – – –
controls in two clusters, the largest of which (135,016 mm3) had
peak localized to the medial aspect of the right superior frontal
gyrus (Table 3 and Supplementary Figure 7).
DISCUSSION
The major findings from this retrospective case series
analysis of 11 patients were: (1) eight patients had
cortical deficits of cerebral glucose metabolism; and (2)
[18F]FDG SUV (i.e., glucose metabolism) was negatively
correlated with Phe, mean historical Phe:Tyr ratio, and
standard deviation in historical Phe:Tyr ratio, across
much of the brain.
We report resting focal hypometabolism on individual visual
analyses for 8 of 11 patients. In contrast, Wasserstein et al.
performed a comparison of relative cerebral glucose metabolic
rates (i.e., whole-brain normalized [18F]FDG uptake) with
healthy controls (Wasserstein et al., 2006), after performance of
a verbal learning task during the uptake period. Our individual
results also extend the findings of Wasserstein et al. to patients
with memory problems, and also to patients with HPA. Whilst
we interpret the results of our between-group comparison with
caution, given that control data were acquired from a different
Centre, we note that like Wasserstein et al. we found bidirectional
alterations in uptake.
To our knowledge this is the first finding of a negative
correlation between cerebral glucose metabolism and mean
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TABLE 3 | Clusters of significantly lower and higher [18F]FDG uptake in patients, relative to healthy controls.
Peak Centre-of-Gravity
Volume (mm3) x, y, z (mm) Region Name x, y, z (mm) Region Name
Patients < Controls 45,464 56, −14, −26 Right inferior and middle temporal gyri 46, −24, −05 Right superior temporal gyrus (middle aspect)
5,816 −04, −22, −20 Brainstem 01, −24, −29 Brainstem
3,168 32, 50, 06 Right middle frontal gyrus 29, 47, 03 Right middle frontal gyrus
672 04, −32, −62 Brainstem −32, −62, 04 Left posterior temporal lobe
56 32, 22, 34 Right middle frontal gyrus 33, 21, 35 Right middle frontal gyrus
Positive 135,016 04, 40, 26 Right superior frontal gyrus (medial aspect) −04, −07, 55 Left superior frontal gyrus (medial aspect)
18,368 06, −88, 10 Right cuneus 03, −73, 05 Right lingual gyrus
Phe:Tyr ratio or standard deviation in Phe:Tyr ratio. Variability in
Phe has been found to be a stronger predictor of poor cognitive
performance than other indices of Phe control including mean
historical Phe (Hood et al., 2014). In our case series analysis
the Phe levels measured within three months of the scan did
not significantly correlate with cerebral glucose metabolism
contrary to Wasserstein et al. (2006; data not shown). However,
similar to Wasserstein et al. (2006), we found a significant
negative correlation with mean historical Phe. Our findings
complement those of Hood et al. (2014) regarding variability and
additionally suggest that Phe:Tyr ratio might be more indicative
of global cerebral glucose metabolism than Phe. A limitation
of the ratio is that blood Tyr is subject to diurnal variation
and is also influenced by food intake; however, this influence
can be minimized by acquiring samples after fasting and/or
averaging several measurements. In those with a high historical
Phe:Tyr ratio, we expect that the elevated blood Phe would
have decreased the concentration of tyrosine in the brain,
due to mutual competition for the large neutral amino acids
type I (LAT1) countertransporter at the blood brain barrier.
The “dopamine depletion” hypothesis (Diamond et al., 1997)
posits that decreased dopamine synthesis results from a state
of cerebral tyrosine deficiency and contributes to cognitive
dysfunction. Noradrenergic neurotransmission is also expected
to be decreased, as it is produced by the metabolism of dopamine.
A serotonin deficiency is also expected as tryptophan also
competes with Phe for LAT1. Our data additionally suggest
that the cerebral tyrosine deficiency is coupled with cerebral
glucose hypometabolism, the mechanism of which remains
to be elucidated. We speculate that cerebral hypometabolism
in classical PKU reflects decreased energy (e.g., dendritic
and astrocytic ion pump) usage via dopaminergic (Landvogt
et al., 2008; Boot et al., 2017), noradrenergic, and serotonergic
neurotransmission. Further exploration of the relationships
between blood biomarkers, cerebral glucose hypometabolism,
structural [e.g., (Perez-Duenas et al., 2006; Vermathen et al.,
2007; Scarabino et al., 2009; Bodner et al., 2012; Christ
et al., 2016] and functional magnetic resonance imaging (fMRI;
(Christ et al., 2010, 2012, 2013)) abnormalities might help
to elucidate the pathophysiological basis of impairment. This
might include measurement of concentrations of the dopamine
metabolite homovanillic acid and the serotonin metabolite
5-hydroxyindoleacetic acid in cerebrospinal fluid, and of
prolactin in serum (secretion of which is inhibited by dopamine).
Our case series analysis is limited due to sample size and the
availability of patient data, which we note was hard to avoid
given it’s retrospective nature and relative low prevalence of
HPA and classical PKU; and by the use of control data from a
different Centre. Whilst we did not distinguish between HPA and
PKU (for statistical power), and the outcomes of these diseases
may differ substantially, all patients complained of memory
problems. The retrospective character of our case series analysis
constitutes an additional limitation, for example resulting in a
lack of data on potential confounds and a lack of standardization
during data collection, which precluded meaningful SUV-IQ and
SUV-diet correlations. Due to their relatively low prevalence,
a prospective multicentre study may be useful to increase
power, allow subgroup analyses based on genotype (e.g., of the
LAT1 countertransporter) or phenotype, and provide a wider
demographic profile, thus increasing validity.
The patients reported in this case series analysis were all
attendees of the Inherited Metabolic & Neuropsychiatry Clinic
who had complained of memory problems, thus the findings
cannot be extrapolated to those without memory complaints.
Further studies are required to confirm the findings are
applicable to the wider PKU/HPA patient population. It was
beyond the scope of our case series analysis to distinguish the
Phe:Tyr – cerebral glucose metabolism relationships between co-
morbidities of interest, such as affective disorders or executive
dysfunction; this could be a valuable insight provided by a
multicentre study.
In conclusion, our case series analysis provides further
evidence for neurocognitive impairment in patients with
classical PKU/HPA, as well as reductions in cerebral glucose
hypometabolism. Mean historical blood Phe:Tyr ratio, and its
standard deviation, appear to be more indicative of global
cerebral glucose metabolism in patients with memory problems
than Phe. Our findings emphasize the need for regulation of Phe
intake in classical PKU/HPA.
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